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Editor,
Imiquimod is a topical immune response modifier used 
in a patient-applied cream to treat genital warts, actinic ke-
ratosis and superficial basal cell carcinomas. It activates the 
immune system through the toll-like receptor 7 (TLR-7).1
Ingenol mebutate is another topically applied drug that 
has been approved for the treatment of actinic keratosis and 
is currently being investigated for the treatment of non-mela-
noma skin cancer.1
Recently I examined a 93 years’ old woman in a pre-co-
ma state, with a round tumor on the zygomatic area of the 
right side of her face with almost six months of evolution. The 
tumor had a hemispheric shape with a central ulceration and 
the size of a chestnut (Fig.s 1and 2). A biopsy showed an epi-
dermoid carcinoma.
It was not possible to transfer the patient to a surgical 
center in order to remove the tumor, taking into account the 
pre-coma state of the patient. Besides, the skin was extremely 
thin and surgery would be very difficult in such conditions.
Therefore, we used imiquimod, which reduced the size of 
the tumor in half. Then, we decided to apply ingenol mebuta-
te 150mcg/g during the three following days and the tumor 
completely regressed in two weeks (Fig. 3).
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We decided to communicate this case in support of those 
who are using these drugs in the treatment of non-melanoma 
skin cancer. We found no similar case but we may recom-
mend trying the association of these two drugs when the sur-
gery is not easy and risky.
REFERENCIE
1. Micali G, Lacarrubba F, Nasca MR, Ferraro S, Schwartz 
RA. Topical pharmacotherapy for skin cancer: part 
II. Clinical applications. J Am Acad Dermatol. 2014; 
70:979.e1-12.
Revista SPDV 73(4); Artur Sousa Basto; Carcinoma epidermóide.
Fig 2 Fig 3 
